Scholar Rock (SRRK)

Market Price (10/27/2026): $41.57 | Market Cap: $5.1 BilSector: Health Care | Industry: Biotechnology

Scholar Rock (SRRK)

Market Price (10/27/2026): $41.57
Market Cap: $5.1 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -406 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%

Key risks
SRRK key risks include [1] manufacturing and regulatory delays for its lead asset, Show more.

0	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
1	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17%
2	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -406 Mil
4	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%
5	Key risks SRRK key risks include [1] manufacturing and regulatory delays for its lead asset, Show more.

SRRK in ETFs

Weight = SRRK's share of each fund

VTI0.01%

ITOT0.01%

IWM0.16%

VB0.03%

XBI0.77%

IWO0.30%

IBB0.29%

VTWO0.18%

+9 more covered ETFs

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	10/27/26	2025	2024	2023	2022
Share Price			$41.57	$44.05	$43.22	$18.80	$9.05
Mkt Cap ($ Bil)			5.1	5.3	4.7	1.7	0.7
+ Debt ($ Bil)			0.2	0.1	0.1	0.1	0.1
- Cash ($ Bil)			0.5	0.4	0.4	0.3	0.3
TEV ($ Bil)			4.8	5.4	4.8	1.8	0.8
Valuation Ratios
P/S	35.5	908.6	-	-	-	-	21.7
P/EBIT	—	—	-13.6	-14.3	-19.5	-10.2	-5.4
P/E	—	—	-13.3	-14.0	-19.2	-10.6	-5.4
P/FCF	—	—	-18.3	-17.7	-23.6	-12.0	-5.4
Sector Ratios (* = sector average)
P/S *			3.7	3.9	3.5	4.2	4.4
P/EBIT *			-1.5	-1.8	-1.2	-1.6	-1.2
P/E *			-1.4	-1.9	-1.5	-1.9	-1.2
P/FCF *			-1.5	-1.7	-1.3	-1.7	-1.4

FYE: 12/31	Forward FYE		Now
	2027	2026	10/27/26
Share Price			$41.57
Mkt Cap ($ Bil)			5.1
+ Debt ($ Bil)			0.2
- Cash ($ Bil)			0.5
TEV ($ Bil)			4.8
Valuation Ratios
P/S	35.5	908.6	-
P/EBIT	—	—	-13.6
P/E	—	—	-13.3
P/FCF	—	—	-18.3
Sector Ratios (* = sector average)
P/S *			3.7
P/EBIT *			-1.5
P/E *			-1.4
P/FCF *			-1.5

FYE: 12/31	SRRK [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$0.0 Mil	—
FY 2026 Sales	$5.6 Mil	—
FY 2027 Sales	$142.4 Mil	—
FY 2026 Sales Growth	—	—
FY 2027 Sales Growth	2,456.4%	13.1%
EARNINGS
LTM Net Income (GAAP) [3]	$-408.6 Mil	—
FY 2026 Net Income (Non-GAAP)	$-418.4 Mil	—
FY 2027 Net Income (Non-GAAP)	$-330.0 Mil	—
FY 2027 Net Income Growth	—	19.2%
FY 2026 EPS (Non-GAAP)	$-3.33	—
FY 2027 EPS (Non-GAAP)	$-2.61	—
FY 2027 EPS Growth	—	—
VALUATION
FY 2026 P/S	908.6	1.7
FY 2027 P/S	35.5	—
FY 2026 P/E	—	8.0
FY 2027 P/E	—	—

[1] SRRK forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 10/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

null

AI Analysis | Feedback

Metric	Value	Date	Source
PDUFA Target Action Date for Apitegromab	September 22, 2025	8142025	Link
Number of Participants in SAPPHIRE Phase 3 Trial (Main Study)	156	10082024	Link
Number of Participants in SAPPHIRE Phase 3 Trial (Ages 13-21 Cohort)	32	10082024	Link
Percentage of SAPPHIRE Trial Patients Enrolled in ONYX Open-Label Expansion Study	98%	10072024	Link
Number of Patients in SAPPHIRE Trial Enrolled in ONYX Open-Label Expansion Study	185	10072024	Link
U.S. Patent Number for Myostatin Inhibitor Combination Therapy	10,946,036	3172021	Link
U.S. Patent Expiry for Myostatin Inhibitor Combination Therapy	June 2037	3172021	Link
U.S. Patent Number for Inhibitors of Myostatin Activation	10,981,981	4262021	Link
U.S. Patent Expiry for Inhibitors of Myostatin Activation	May 2034	4262021	Link

Price Chart

null

No Events

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 10/13/2026

Scholar Rock (SRRK) stock has lost about 25% since 6/30/2026 because of the following key factors:

1. European Regulatory Delays and Facility Issues.

Scholar Rock faced a significant setback in its European commercialization efforts during the period, contributing to investor uncertainty. The company withdrew its Marketing Authorisation Application (MAA) for apitegromab in Europe in August 2026 due to issues with GMP compliance at the Catalent Indiana fill-finish facility. While the MAA was resubmitted on October 8, 2026, with an alternate facility, this introduced a delay, pushing the anticipated European Medicines Agency (EMA) opinion to the first half of 2027, from an earlier expectation of mid-2026.

2. Commercialization Concerns Following FDA Approval and Fracture Risk.

Although the U.S. Food and Drug Administration (FDA) approved ISEMBYLD (apitegromab-mstn) on September 11, 2026, for spinal muscular atrophy (SMA), concerns regarding its commercial uptake emerged. The drug's label included a warning for fracture risk. A September 2026 survey indicated that while physicians generally viewed the drug's efficacy as clinically meaningful, many reported a lower willingness to prescribe it to patients with existing skeletal risk factors. This safety concern, post-approval, could temper initial adoption rates and impact revenue projections.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -24.2% change in SRRK stock from 6/30/2026 to 10/26/2026 was primarily driven by a -2.6% change in the company's Shares Outstanding (Mil).

(LTM values as of)	6302026	10262026	Change
Stock Price ($)	55.00	41.71	-24.2%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	127	131	-2.6%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2026 to 10/26/2026

	Return	Correlation
SRRK	-24.2%
Market (SPY)	2.5%	13.4%
Sector (XLV)	13.0%	15.9%

Fundamental Drivers

The -15.2% change in SRRK stock from 3/31/2026 to 10/26/2026 was primarily driven by a -7.7% change in the company's Shares Outstanding (Mil).

(LTM values as of)	3312026	10262026	Change
Stock Price ($)	49.16	41.71	-15.2%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	121	131	-7.7%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2026 to 10/26/2026

	Return	Correlation
SRRK	-15.2%
Market (SPY)	18.0%	13.8%
Sector (XLV)	22.8%	18.9%

Fundamental Drivers

The 12.0% change in SRRK stock from 9/30/2025 to 10/26/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	9302025	10262026	Change
Stock Price ($)	37.24	41.71	12.0%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	113	131	-13.7%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 10/26/2026

	Return	Correlation
SRRK	12.0%
Market (SPY)	15.8%	21.1%
Sector (XLV)	30.5%	17.9%

Fundamental Drivers

The 487.5% change in SRRK stock from 9/30/2023 to 10/26/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	9302023	10262026	Change
Stock Price ($)	7.10	41.71	487.5%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	80	131	-38.7%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2023 to 10/26/2026

	Return	Correlation
SRRK	487.5%
Market (SPY)	85.2%	5.5%
Sector (XLV)	45.8%	5.9%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
SRRK Return	-49%	-64%	108%	130%	2%	-6%	-15%
Peers Return	-20%	19%	-1%	-0%	27%	-7%	11%
S&P 500 Return	27%	-19%	24%	23%	16%	11%	103%
Monthly Win Rates [3]
SRRK Win Rate	42%	42%	50%	58%	42%	50%
Peers Win Rate	47%	58%	48%	47%	52%	46%
S&P 500 Win Rate	75%	42%	67%	75%	67%	40%
Max Drawdowns [4]
SRRK Max Drawdown	-65%	-81%	-54%	-62%	-48%	-34%
Peers Max Drawdown	-47%	-30%	-38%	-37%	-43%	-33%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: BIIB, IONS, SRPT, PTCT, REGN. See SRRK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/26/2026 (YTD)

Event	SRRK	S&P 500
2025 US Tariff Shock
% Loss	-35.6%	-18.8%
% Gain to Breakeven	55.3%	23.1%
Time to Breakeven	93 days	79 days
2023 SVB Regional Banking Crisis
% Loss	-42.1%	-6.7%
% Gain to Breakeven	72.7%	7.1%
Time to Breakeven	149 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-81.1%	-24.5%
% Gain to Breakeven	429.6%	32.4%
Time to Breakeven	859 days	427 days
2020 COVID-19 Crash
% Loss	-27.4%	-33.7%
% Gain to Breakeven	37.7%	50.9%
Time to Breakeven	2 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-32.7%	-19.2%
% Gain to Breakeven	48.6%	23.8%
Time to Breakeven	651 days	105 days

Compare to BIIB, IONS, SRPT, PTCT, REGN

In The Past

Scholar Rock's stock fell -35.6% during the 2025 US Tariff Shock. Such a loss loss requires a 55.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	SRRK	S&P 500
2025 US Tariff Shock
% Loss	-35.6%	-18.8%
% Gain to Breakeven	55.3%	23.1%
Time to Breakeven	93 days	79 days
2023 SVB Regional Banking Crisis
% Loss	-42.1%	-6.7%
% Gain to Breakeven	72.7%	7.1%
Time to Breakeven	149 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-81.1%	-24.5%
% Gain to Breakeven	429.6%	32.4%
Time to Breakeven	859 days	427 days
2020 COVID-19 Crash
% Loss	-27.4%	-33.7%
% Gain to Breakeven	37.7%	50.9%
Time to Breakeven	2 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-32.7%	-19.2%
% Gain to Breakeven	48.6%	23.8%
Time to Breakeven	651 days	105 days

Compare to BIIB, IONS, SRPT, PTCT, REGN

In The Past

Scholar Rock's stock fell -35.6% during the 2025 US Tariff Shock. Such a loss loss requires a 55.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Scholar Rock (SRRK)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Scholar Rock (SRRK) is a biopharmaceutical company focused on discovering and developing novel medicines for serious diseases where protein growth factor signaling is a key factor. The company aims to address unmet medical needs in areas such as neuromuscular disorders, various cancers, and fibrotic diseases by targeting these specific biological pathways with innovative therapeutic candidates.

The company's lead product candidate, Apitegromab, has completed Phase 3 clinical trials and is being developed for the treatment of Spinal Muscular Atrophy (SMA). Additionally, Scholar Rock is advancing SRK-181 through Phase 1 clinical trials, which targets cancers that have become resistant to existing checkpoint inhibitor therapies, such as anti-PD-1 treatments. The company also maintains a broader pipeline of product candidates and has a strategic collaboration with Gilead Sciences, Inc. to discover and develop specific inhibitors for transforming growth factor beta activation, intended for fibrotic diseases.

AI Analysis | Feedback

1. An early-stage Vertex Pharmaceuticals focused on rare neuromuscular disorders.

2. A developing biotech similar to Biogen, with drugs for neurological diseases, cancer, and fibrosis.

AI Analysis | Feedback

Scholar Rock's major products are experimental drug candidates in various stages of clinical development:

Apitegromab: An inhibitor designed to treat spinal muscular atrophy, having completed Phase 3 clinical trials.
SRK-181: A drug candidate in Phase 1 clinical trials targeting cancers resistant to checkpoint inhibitor therapies.
Novel product candidates: A pipeline of developing therapies aimed at neuromuscular disorders, cancer, and fibrosis.
TGFβ inhibitors: Specific inhibitors of transforming growth factor beta activation being discovered and developed in collaboration with Gilead Sciences for fibrotic diseases.

AI Analysis | Feedback

Scholar Rock (SRRK) is a biopharmaceutical company focused on the discovery and development of medicines. Given its stage of development, with drug candidates primarily in clinical trials, it does not currently have major customers in the traditional sense of selling finished products directly to individuals or end-users.

Instead, its revenue or strategic relationships typically come from collaborations or partnerships with larger pharmaceutical companies that license, co-develop, or acquire its drug candidates. Based on the provided description, the company sells primarily to other companies in this context.

The major customer or strategic partner explicitly mentioned in the background information is:

Gilead Sciences, Inc. (GILD)

AI Analysis | Feedback

null

AI Analysis | Feedback

David Hallal
Chief Executive Officer & Chairman

David Hallal was appointed Chief Executive Officer in April 2025 and has served as Chairman of Scholar Rock's Board of Directors since 2017. Prior to joining Scholar Rock, he spent over a decade as CEO, COO, and CCO of Alexion, where he was responsible for building and leading the company's 50-country operating platform.

Vikas Sinha
Chief Financial Officer

Vikas Sinha was appointed Chief Financial Officer in April 2025. He previously held the position of Chief Financial Officer at Alexion and ElevateBio.

Akshay Vaishnaw M.D., Ph.D.
President, R&D

Akshay Vaishnaw was appointed to the newly created role of President of Research & Development in April 2025. He has been a member of Scholar Rock's Board of Directors since 2019 and previously served as President of Alnylam.

R. Keith Woods
Chief Operating Officer

R. Keith Woods was appointed to the newly created role of Chief Operating Officer in April 2025, with a focus on evolving the organization into a fully integrated global commercial enterprise. He was formerly the Chief Operating Officer of argenx.

Lisa Wyman
Chief Technical and Quality Officer

Lisa Wyman was appointed Chief Technical and Quality Officer in January 2025. She brings over 20 years of leadership and functional experience in technical and quality operations, including executive team responsibilities at Generate:Biomedicines and Acceleron Pharma. Acceleron Pharma was acquired by Merck in 2021.

AI Analysis | Feedback

Key Risks for Scholar Rock (SRRK)

Regulatory approval and commercial success of lead product candidates: Scholar Rock's future revenue and profitability are heavily dependent on the successful regulatory approval and subsequent commercialization of its lead product candidate, Apitegromab, which has completed Phase 3 clinical trials for spinal muscular atrophy. There is no guarantee that Apitegromab will receive regulatory approval or achieve significant market acceptance, which would severely impact the company's business and financial prospects. Similarly, the success of other pipeline candidates, such as SRK-181 (in Phase 1 clinical trials), is critical but also uncertain.
Reliance on a limited number of product candidates: The company's business model is significantly concentrated around the successful development and commercialization of a small number of product candidates, primarily Apitegromab and SRK-181. A setback, failure in clinical trials, or adverse regulatory decision for either of these key programs could have a disproportionately negative impact on Scholar Rock's financial condition and ability to continue operations.

AI Analysis | Feedback

null

AI Analysis | Feedback

Apitegromab (Spinal Muscular Atrophy)

The addressable market for Apitegromab in the treatment of spinal muscular atrophy (SMA) is substantial. In the U.S. market, Apitegromab's revenue is projected to reach an annual total of $433 million by 2037. Globally, the spinal muscular atrophy treatment market size was estimated at USD 4.40 billion in 2024 and is projected to reach USD 13.09 billion by 2030, growing at a CAGR of 18.0% from 2025 to 2030. Another source projects the global spinal muscular atrophy therapeutics market to rise from USD 6.06 billion in 2026 to USD 13.48 billion by 2031. Scholar Rock plans to launch apitegromab commercially in the US and Europe in 2026 and aims to expand its market reach to 50 countries, targeting 35,000 SMA patients. Analyst estimates indicate peak sales for Apitegromab could reach $1.5 billion.

SRK-181 (Cancers Resistant to Checkpoint Inhibitor Therapies)

SRK-181 targets cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. The global market for checkpoint inhibitor refractory cancer drugs was estimated at USD 42,632.94 million in 2025 and is expected to grow to USD 95,548.35 million by 2032, at a Compound Annual Growth Rate (CAGR) of 12.67% from 2025 to 2032. This market encompasses the expanding patient pool that does not respond to, or progresses after, PD-(L)1 and CTLA-4 checkpoint inhibitor therapy.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Scholar Rock (SRRK)

Over the next 2-3 years, Scholar Rock Holding Corporation's future revenue growth is primarily anticipated to be driven by the following key factors:

U.S. Commercial Launch and Ramp-up of Apitegromab for Spinal Muscular Atrophy (SMA): Scholar Rock is preparing for the U.S. commercial launch of apitegromab in 2026, following a constructive meeting with the FDA and progress in addressing manufacturing facility observations. This therapy aims to be the first muscle-targeted treatment approved for both children and adults with SMA.
European Commercial Launch and Expansion of Apitegromab for SMA: Following the anticipated U.S. launch, a regulatory decision from the European Medicines Agency (EMA) is expected by mid-2026, with a European launch projected for the second half of 2026, starting with Germany. This will open up significant international market access for apitegromab.
Global Market Expansion of Apitegromab: Beyond the initial U.S. and European markets, Scholar Rock plans to establish a 50-country operating platform, targeting a broad patient population of approximately 35,000 SMA patients, with a focus on expansion into regions like Asia-Pacific and Latin America.
Advancement of Apitegromab into Additional Indications and Formulations: The company is actively pursuing the expansion of apitegromab's market potential through further clinical development. This includes the Phase 2 OPAL study evaluating apitegromab in combination with gene therapy for infants and toddlers under two years old with SMA. Additionally, Scholar Rock is exploring the development of a subcutaneous version of apitegromab, which could broaden its administration options and patient reach following the approval of the intravenous formulation.

AI Analysis | Feedback

Share Issuance

Scholar Rock completed an upsized public offering of common stock and pre-funded warrants in October 2024, generating approximately $300 million in gross proceeds to support commercialization, advance clinical programs, and for general corporate purposes.
The company reported $60.4 million from warrant exercises in the fourth quarter of 2025, contributing to its cash balance.

Inbound Investments

Scholar Rock secured a new debt facility of up to $550 million with Blue Owl Capital, with an additional $100 million expected to be drawn by the end of the first quarter of 2026, to support commercial and pipeline initiatives.
The company anticipates monetizing a rare pediatric disease priority review voucher, potentially valued between $150 million and $200 million, upon apitegromab approval.

Capital Expenditures

Annual capital expenditures were $5.25 million in 2021, $1.06 million in 2022, $0.06 million in 2023, $0.10 million in 2024, and $0.60 million in 2025.
Current and planned capital expenditures are focused on commercial readiness and inventory build-out for apitegromab, advancing clinical programs, and developing its technology platform.
The company is investing in a second U.S. fill-finish facility to strengthen supply continuity and support future commercial demand for apitegromab.

Interactive Breakdown

null

null

Better Bets vs. Scholar Rock (SRRK)

null

Peer Outperformance in Biotechnology

SRRK has outperformed 86% of its 362 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.

Share of Biotechnology constituents that SRRK has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.

81%

of 453 industry peers · 40.5% return

89%

of 398 industry peers · 303.4% return

86%

of 362 industry peers · 60.1% return

No Biotechnology peer with a comparable growth profile has beaten SRRK by more than 20pp over 5Y.

Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is SRRK's own industry. Use this to see which corners of the sector have carried the returns.

Industry	Names	1Y med	3Y med	5Y med	Top 3 by 5Y
Health Care Distributors	6	12.1%	53.8%	97.6%	CAH 472% · MCK 389% · COR 183%
Health Care Services	20	18.7%	47.4%	15.5%	HIMS 255% · RDNT 126% · DGX 84%
Health Care Facilities	24	4.8%	32.5%	5.4%	THC 294% · NHC 270% · ENSG 154%
Managed Health Care	8	26.9%	1.8%	-2.6%	OSCR 83% · HQY 53% · ELV 6%
Health Care Equipment	50	-1.4%	12.6%	-16.3%	UFPT 369% · GKOS 303% · TMDX 162%
Pharmaceuticals	60	-15.0%	9.7%	-32.2%	LQDA 1098% · KNSA 588% · LLY 439%
Health Care Supplies	11	16.2%	0.6%	-38.7%	LNTH 337% · HAE 66% · MMSI 36%
Life Sciences Tools & Services	107	-3.5%	3.0%	-67.0%	NTRA 249% · MEDP 218% · AXGN 166%
Health Care Technology	21	-34.0%	-59.9%	-81.4%	VEEV -1% · DOCS -50%
Biotechnology ←	363	-28.2%	-23.4%	-81.8%	DNTH 1113% · ELVN 1046% · ADMA 720%

Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	null	06/30/2026
2	Scholar Rock Earnings Notes	12/26/2025
3	SRRK Dip Buy Analysis	07/10/2025
4	Scholar Rock Total Shareholder Return (TSR): 129.9% in 2024 and 20.3% 3-yr compounded annual returns (above peer average)	03/07/2025
5	Scholar Rock (SRRK) Operating Cash Flow Comparison	02/17/2025
6	Scholar Rock (SRRK) Net Income Comparison	02/16/2025
7	Scholar Rock (SRRK) Operating Income Comparison	02/15/2025
8	ARTICLES
9	Where The Buying Ran Strongest: 24 Small Cap Stocks At 52-Week Highs	08/27/2026
10	Scholar Rock Stock On Fire: Up 21% With 8-Day Winning Streak	06/30/2026
11	Scholar Rock Stock Rockets 20% With 7-Day Winning Streak	06/29/2026
12	Small Cap Stocks Trading At 52-Week High	05/15/2026
13	Market Movers \| Winners: GES, SRRK, NESR \| Losers: CLDX, LZB, OPEN	08/21/2025

	Title
0	DASHBOARDS
1	null
2	Scholar Rock Earnings Notes
3	SRRK Dip Buy Analysis
4	Scholar Rock Total Shareholder Return (TSR): 129.9% in 2024 and 20.3% 3-yr compounded annual returns (above peer average)
5	Scholar Rock (SRRK) Operating Cash Flow Comparison
6	Scholar Rock (SRRK) Net Income Comparison
7	Scholar Rock (SRRK) Operating Income Comparison
8	ARTICLES
9	Where The Buying Ran Strongest: 24 Small Cap Stocks At 52-Week Highs
10	Scholar Rock Stock On Fire: Up 21% With 8-Day Winning Streak
11	Scholar Rock Stock Rockets 20% With 7-Day Winning Streak
12	Small Cap Stocks Trading At 52-Week High
13	Market Movers \| Winners: GES, SRRK, NESR \| Losers: CLDX, LZB, OPEN

Trade Ideas

Select ideas related to SRRK.

null

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
SGRY	Surgery Partners	3.0	47.6%	50.5%
SWRD	Stewards	-	21.6%	-40.4%
RPD	Rapid7	1.2	20.3%	18.0%
RRC	Range Resources	12.6	17.7%	53.0%
XNCR	Xencor	2.2	15.9%	90.6%
MYPS	PLAYSTUDIOS	0.6	13.7%	562.6%
ORKA	Oruka Therapeutics	5.7	12.7%	198.0%
BLSM	BlossomHill Therapeutics	-	12.0%	2.4%
NN	NextNav	1.6	11.9%	-32.2%
VICR	Vicor	8.9	10.6%	77.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ORIC	ORIC Pharmaceuticals	1.0	-32.0%	9.5%
AVBP	ArriVent BioPharma	0.7	-26.9%	-23.7%
CLYM	Climb Bio	0.7	-13.5%	120.3%
AMCX	AMC Global Media	0.3	-13.5%	-16.6%
TRON	Tron	0.6	-13.2%	0.4%
FICO	Fair Isaac	16.1	-13.2%	-58.1%
JBLU	JetBlue Airways	0.9	-9.7%	-47.9%
DAVE	Dave	4.1	-8.9%	45.9%
FMC	FMC	0.6	-8.7%	-66.1%
MBC	MasterBrand	1.0	-8.5%	-39.5%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
SGRY	Surgery Partners	3.0	58.1%	50.5%
BRZE	Braze	5.1	52.6%	33.7%
RHI	Robert Half	4.5	36.8%	75.9%
RPD	Rapid7	1.2	35.6%	18.0%
NTSK	Netskope	10.1	29.8%	43.7%
LQDA	Liquidia	3.9	28.2%	26.8%
HPP	Hudson Pacific Properties	0.7	26.1%	5.0%
XNCR	Xencor	2.2	25.8%	90.6%
FMCC	Federal Home Loan Mortgage	12.7	25.2%	-61.2%
RRC	Range Resources	12.6	23.9%	53.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AVTX	Avalo Therapeutics	0.3	-41.6%	-62.7%
ORIC	ORIC Pharmaceuticals	1.0	-29.6%	9.5%
KALU	Kaiser Aluminum	1.7	-29.3%	-6.2%
AVEX	AEVEX	0.6	-26.3%	-60.3%
NVEC	NVE	0.4	-24.9%	31.9%
CRS	Carpenter Technology	14.4	-23.5%	-7.9%
CORT	Corcept Therapeutics	9.2	-22.3%	150.4%
AMCX	AMC Global Media	0.3	-20.9%	-16.6%
FPS	Forgent Power Solutions	6.1	-20.3%	-13.4%
USAS	Americas Gold And Silver	1.0	-20.2%	-41.1%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
KOD	Kodiak Sciences	5.6	177.0%	220.5%
BRZE	Braze	5.1	88.1%	33.7%
SGRY	Surgery Partners	3.0	61.5%	50.5%
FIGS	FIGS	3.5	55.2%	83.4%
RPD	Rapid7	1.2	54.3%	18.0%
DXC	DXC Technology	2.7	53.1%	11.3%
HPK	HighPeak Energy	1.4	50.7%	140.3%
RXO	RXO	4.9	44.9%	126.9%
PCRX	Pacira BioSciences	1.4	44.8%	40.6%
TENB	Tenable	5.3	44.0%	104.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
GLAS	Glass House Brands	0.2	-68.5%	-75.8%
NUAI	New Era Energy & Digital	0.3	-57.9%	1.4%
SHAZ	SharonAI	0.4	-57.0%	-74.6%
CIFR	Cipher Digital	3.2	-56.5%	-47.8%
AVTX	Avalo Therapeutics	0.3	-56.2%	-62.7%
EMAT	Evolution Metals & Technologies	0.9	-55.9%	-93.4%
BRUN	Boost Run	0.5	-55.4%	-64.3%
FMC	FMC	0.6	-51.5%	-66.1%
EOSE	Eos Energy Enterprises	0.6	-48.8%	-85.9%
XNDU	Xanadu Quantum Technologies	0.8	-48.6%	-77.7%

Peer Comparisons

Peers to compare with:

Financials

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
Mkt Price	42.71	251.37	43.85	18.35	61.24	813.63	52.55
Mkt Cap	5.6	37.1	7.3	1.9	5.1	83.6	6.4
Rev LTM	0	10,028	874	1,974	1,009	15,535	1,492
Op Inc LTM	-406	1,935	-594	-62	117	4,174	27
FCF LTM	-297	2,490	-568	75	-333	3,575	-111
FCF 3Y Avg	-241	1,935	-410	-302	37	3,439	-102
CFO LTM	-297	2,879	-496	111	-31	4,681	40
CFO 3Y Avg	-241	2,260	-358	-195	186	4,498	-5

Growth & Margins

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
Rev Chg LTM	-	0.3%	-7.4%	-20.4%	-42.8%	9.3%	-7.4%
Rev Chg 3Y Avg	-	0.2%	12.5%	31.5%	21.0%	7.0%	12.5%
Rev Chg Q	-	3.4%	-40.7%	-34.3%	101.5%	16.7%	3.4%
QoQ Delta Rev Chg LTM	-	0.9%	-17.4%	-9.6%	22.0%	4.1%	0.9%
Op Inc Chg LTM	-25.7%	-21.7%	-123.0%	-6,578.0%	-86.5%	6.1%	-56.1%
Op Inc Chg 3Y Avg	-35.9%	-6.0%	-24.5%	-2,191.0%	174.3%	-1.7%	-15.2%
Op Mgn LTM	-	19.3%	-68.0%	-3.2%	11.6%	26.9%	11.6%
Op Mgn 3Y Avg	-	21.5%	-47.0%	-0.2%	13.1%	28.2%	13.1%
QoQ Delta Op Mgn LTM	-	-3.9%	-34.7%	-3.2%	19.7%	1.1%	-3.2%
CFO/Rev LTM	-	28.7%	-56.8%	5.6%	-3.0%	30.1%	5.6%
CFO/Rev 3Y Avg	-	22.8%	-41.2%	-10.9%	8.0%	31.2%	8.0%
FCF/Rev LTM	-	24.8%	-64.9%	3.8%	-33.0%	23.0%	3.8%
FCF/Rev 3Y Avg	-	19.5%	-47.1%	-16.5%	-6.9%	23.9%	-6.9%

Valuation

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
Mkt Cap	5.6	37.1	7.3	1.9	5.1	83.6	6.4
P/S	-	3.7	8.3	1.0	5.0	5.4	5.0
P/Op Inc	-13.7	19.2	-12.2	-31.1	43.5	20.0	3.5
P/EBIT	-14.0	28.6	-15.1	-32.6	43.0	16.0	1.0
P/E	-13.7	44.5	-12.8	-14.2	-132.4	19.3	-13.2
P/CFO	-18.8	12.9	-14.6	17.4	-166.7	17.9	-0.9
Total Yield	-7.5%	2.2%	-7.9%	-7.2%	-0.8%	5.7%	-4.0%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.0%
FCF Yield 3Y Avg	-10.5%	7.2%	-4.8%	-8.9%	0.9%	4.9%	-1.9%
D/E	0.0	0.2	0.2	0.5	0.1	0.0	0.2
Net D/E	-0.1	0.2	-0.1	0.1	-0.3	-0.1	-0.1

Returns

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
1M Rtn	-12.2%	10.4%	-1.5%	-1.7%	-2.3%	3.2%	-1.6%
3M Rtn	-12.7%	25.6%	-21.6%	15.5%	-19.2%	22.1%	1.4%
6M Rtn	-7.7%	39.1%	-39.3%	-12.5%	-11.5%	9.6%	-9.6%
12M Rtn	43.9%	67.7%	-38.1%	-19.6%	-7.8%	41.5%	16.9%
3Y Rtn	313.1%	7.2%	-0.5%	-82.8%	230.8%	6.0%	6.6%
1M Excs Rtn	-10.6%	12.0%	0.1%	-0.1%	-0.7%	4.8%	-0.0%
3M Excs Rtn	-16.2%	19.6%	-23.4%	16.2%	-21.4%	14.5%	-0.8%
6M Excs Rtn	-14.2%	32.9%	-45.6%	-18.9%	-17.8%	3.3%	-16.0%
12M Excs Rtn	35.6%	54.4%	-51.9%	-29.6%	-21.5%	28.8%	3.7%
3Y Excs Rtn	389.4%	-80.2%	-84.8%	-163.6%	81.4%	-77.2%	-78.7%

Comparison Analyses

	Title
0	Scholar Rock Holding vs bluebird bio: Industry Peers; Which Stock Is A Better Bet?
1	Scholar Rock Holding vs Varex Imaging: Similar Market Cap; Which Stock Is A Better Bet?
2	Scholar Rock Holding vs 1-800-FLOWERS.COM: Similar Market Cap; Which Stock Is A Better Bet?
3	Scholar Rock Holding vs Tupperware Brands: Similar Market Cap; Which Stock Is A Better Bet?
4	Scholar Rock Holding vs Adamis Pharmaceuticals: Similar Revenue; Which Stock Is A Better Bet?
5	Scholar Rock Holding vs Alpine Management Systems: Similar Revenue; Which Stock Is A Better Bet?

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for More

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
BLA761463	ISEMBYLD	apitegromab-mstn	injectable	9112026	-24.7%	-24.7%	-24.7%	-24.7%	-24.7%

Collapse to Preview

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
BLA761463	ISEMBYLD	apitegromab-mstn	injectable	9112026	-24.7%	-24.7%	-24.7%	-24.7%	-24.7%

Clinical Pipeline

null

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	6/30/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	8/6/2026	3/3/2026	2/27/2025	3/19/2024	3/7/2023	3/7/2022	3/9/2021
Key Financials
Total Revenue	0	0	0	0	33	19	15
Gross Profit	-	-	-	-	-	-	-
EBITDA	-396	-369	-238	-168	-131	-127	-85
Operating Income	-406	-385	-252	-171	-134	-130	-87
Net Income	-409	-378	-246	-166	-135	-132	-86
EPS	-3.45	-3.29	-2.47	-1.99	-2.26	-3.59	-2.81
Growth Rates
Total Revenue Growth	-	-	-	-100.0%	76.4%	22.2%	-24.8%
EBITDA Growth	-28.9%	-55.5%	-41.0%	-28.2%	-3.2%	-49.1%	-60.4%
Operating Income Growth	-25.7%	-52.6%	-47.1%	-27.5%	-3.4%	-49.5%	-59.3%
Net Income Growth	-29.4%	-53.5%	-48.6%	-23.3%	-2.1%	-52.4%	-69.6%
Margins
Gross Margin	-	-	-	-	-	-	-
EBITDA Margin	-	-	-	-	-395.8%	-676.5%	-554.4%
Operating Income Margin	-	-	-	-	-404.8%	-690.5%	-564.0%
Net Income Margin	-	-	-	-	-405.2%	-700.5%	-561.5%
Cash & Debt
Total Cash	492	368	437	280	315	253	341
Total Debt	204	109	65	62	69	77	57
Net Debt / (Cash)	-288	-259	-372	-218	-246	-176	-284
Cash Flows & CapEx
Net Cash from Operations	-297	-300	-201	-145	-133	-127	-60
Total CapEx	-0	-1	-0	-0	-1	-5	-4
Free Cash from Operations	-297	-301	-201	-145	-134	-132	-64
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3
Period End	6/30/2026	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023
Filing Date	8/6/2026	5/7/2026	3/3/2026	11/14/2025	8/6/2025	5/14/2025	2/27/2025	11/12/2024	8/8/2024	5/7/2024	3/19/2024	11/7/2023
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-105	-103	-88	-100	-108	-73	-64	-62	-56	-58	-47	-43
Operating Income	-109	-102	-92	-104	-112	-77	-69	-65	-59	-58	-48	-44
Net Income	-110	-106	-91	-102	-110	-75	-66	-64	-59	-57	-46	-42
EPS	-0.84	-0.83	-0.88	-0.90	-0.98	-0.67	-0.61	-0.66	-0.60	-0.59	-0.50	-0.53
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda TTM	-396	-400	-369	-346	-308	-256	-241	-224	-204	-186	-168	-161
Operating Income TTM	-406	-410	-385	-362	-323	-271	-252	-231	-210	-189	-171	-164
Net Income TTM	-409	-409	-378	-353	-316	-264	-246	-226	-204	-183	-166	-159
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Growth	3.1%	-41.9%	-36.6%	-61.3%	-92.6%	-25.4%	-36.0%	-45.0%	-46.8%	-45.4%	-19.4%	0.4%
Operating Income Growth	2.9%	-32.3%	-32.5%	-59.8%	-88.4%	-32.0%	-44.4%	-48.3%	-52.2%	-44.2%	-18.8%	0.4%
Net Income Growth	0.1%	-41.2%	-36.9%	-58.5%	-88.1%	-31.4%	-44.1%	-52.2%	-54.3%	-44.4%	-17.5%	2.2%
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	492	480	368	370	295	364	437	139	190	238	280	219
Total Debt	204	206	109	110	62	63	65	67	68	60	62	63
Net Debt / (Cash)	-288	-274	-259	-260	-233	-301	-372	-72	-122	-178	-218	-155
Cash Flows Quarterly
FCF from Operations	-70	-82	-75	-69	-77	-79	-50	-52	-49	-50	-37	-32
Cash Flows TTM
FCF from Operations TTM	-297	-303	-300	-274	-258	-230	-201	-189	-169	-152	-145	-137
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-29.4%	-29.0%	-28.6%	-34.7%	-40.5%	-30.6%	-30.2%	-30.0%	-29.6%	-31.7%	-28.1%	-27.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-27.4%	-29.1%	-29.9%	-30.3%	-29.2%	-26.8%	-27.4%	-26.7%	-26.1%	-25.6%	-25.1%	-25.5%

Segment Financials

Revenue by Segment

$ Mil	2023	2022	2021	2020	2019
Single Segment	0	33	19	15	20
Total	0	33	19	15	20

Net Income by Segment

$ Mil	2025	2024
Single Segment	-378	-246
Total	-378	-246

Assets by Segment

$ Mil	2024	2023	2018	2017
Single Segment	475	311	181	62
Total	475	311	181	62

Price Behavior

Price Behavior

Market Price	$41.71
Market Cap ($ Bil)	5.4
First Trading Date	05/24/2018
Distance from 52W High	-30.5%
	50 Days	200 Days
DMA Price	$49.36	$48.21
DMA Trend	down	indeterminate
Distance from DMA	-15.5%	-13.5%
	3M	1YR
Volatility	48.1%	55.7%
Downside Capture	96.81	54.28
Upside Capture	-8.98	90.35
Correlation (S&P 500)	13.0%	24.8%

SRRK Betas & Captures as of 9/30/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.21	0.73	0.49	0.43	0.95	0.78
Up Beta	2.01	-0.47	0.06	0.54	1.41	1.26
Down Beta	0.72	1.32	-0.62	-0.04	1.18	0.85
Up Capture	38%	108%	54%	37%	73%	183%
Bmk +ve Days	6	16	27	66	132	424
Stock +ve Days	8	20	30	64	125	368
Down Capture	292%	108%	138%	74%	73%	86%
Bmk -ve Days	16	26	37	60	120	328
Stock -ve Days	14	22	34	62	127	380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with SRRK
SRRK	45.8%	55.7%	0.86	-
Sector ETF (XLV)	24.4%	16.3%	1.15	21.3%
Equity (SPY)	14.9%	12.7%	0.81	24.8%
Gold (GLD)	-2.9%	28.5%	-0.12	8.2%
Commodities (DBC)	48.1%	20.6%	1.79	-12.1%
Real Estate (VNQ)	4.9%	13.9%	0.10	16.5%
Bitcoin (BTCUSD)	-26.4%	43.5%	-0.59	13.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with SRRK
SRRK	9.5%	179.3%	0.42	-
Sector ETF (XLV)	8.8%	15.3%	0.38	9.3%
Equity (SPY)	12.8%	17.1%	0.56	10.1%
Gold (GLD)	17.4%	18.9%	0.74	-0.1%
Commodities (DBC)	9.4%	19.5%	0.36	2.8%
Real Estate (VNQ)	1.2%	18.9%	-0.05	9.1%
Bitcoin (BTCUSD)	5.5%	51.7%	0.29	7.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with SRRK
SRRK	10.4%	154.5%	0.46	-
Sector ETF (XLV)	11.8%	16.8%	0.58	10.0%
Equity (SPY)	15.4%	17.9%	0.73	10.7%
Gold (GLD)	11.9%	16.4%	0.59	0.1%
Commodities (DBC)	8.3%	18.1%	0.37	4.3%
Real Estate (VNQ)	5.3%	20.7%	0.21	6.9%
Bitcoin (BTCUSD)	62.3%	66.2%	1.02	4.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	9302026
Short Interest: Shares Quantity	22.7 Mil
Short Interest: % Change Since 9152026	17.1%
Average Daily Volume	2.4 Mil
Days-to-Cover Short Interest	9.3 days
Basic Shares Quantity	130.6 Mil
Short % of Basic Shares	17.4%

Returns Analyses

	Title
0	Scholar Rock Stock Return Comparison
1	[10/3/2021] Scholar Rock Holding (SRRK) Stock Price Forecast: AI Forecasts SRRK Stock Price To Be Around $35.7 In A Month (Up 12%)

Earnings Returns History

Updated 8/6/2026

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/7/2026	-1.4%	6.5%	-6.0%
3/3/2026	1.9%	1.7%	13.1%
1/12/2026	3.3%	6.6%	12.9%
11/14/2025	24.4%	26.4%	47.4%
8/6/2025	-6.4%	-12.9%	-12.3%
5/14/2025	-2.7%	0.4%	6.1%
2/27/2025	-2.9%	-2.4%	-9.9%
11/12/2024	-5.3%	-6.3%	49.8%
...
SUMMARY STATS
# Positive	17	17	13
# Negative	9	9	13
Median Positive	5.8%	6.6%	9.6%
Median Negative	-2.5%	-6.3%	-9.9%
Max Positive	24.4%	32.5%	49.8%
Max Negative	-6.4%	-18.8%	-44.6%

Collapse to Preview

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/7/2026	-1.4%	6.5%	-6.0%
3/3/2026	1.9%	1.7%	13.1%
1/12/2026	3.3%	6.6%	12.9%
11/14/2025	24.4%	26.4%	47.4%
8/6/2025	-6.4%	-12.9%	-12.3%
5/14/2025	-2.7%	0.4%	6.1%
2/27/2025	-2.9%	-2.4%	-9.9%
11/12/2024	-5.3%	-6.3%	49.8%
8/8/2024	-1.0%	11.6%	-2.7%
5/7/2024	-2.5%	-9.4%	-34.7%
3/19/2024	14.8%	21.3%	3.8%
1/8/2024	5.8%	1.2%	-1.1%
11/7/2023	1.5%	-18.8%	30.9%
8/9/2023	11.3%	9.0%	1.0%
5/9/2023	6.0%	3.7%	-15.8%
3/7/2023	6.6%	2.3%	-13.2%
11/14/2022	1.1%	0.2%	-0.9%
8/8/2022	6.7%	32.5%	4.9%
5/16/2022	15.0%	-0.6%	-3.3%
3/7/2022	3.7%	-9.5%	-9.9%
11/9/2021	3.8%	24.1%	-8.2%
8/10/2021	3.5%	12.1%	3.3%
5/13/2021	-0.5%	-3.9%	10.6%
3/9/2021	8.3%	15.8%	-44.6%
11/9/2020	-0.5%	2.8%	9.6%
8/7/2020	2.3%	-0.2%	5.0%
SUMMARY STATS
# Positive	17	17	13
# Negative	9	9	13
Median Positive	5.8%	6.6%	9.6%
Median Negative	-2.5%	-6.3%	-9.9%
Max Positive	24.4%	32.5%	49.8%
Max Negative	-6.4%	-18.8%	-44.6%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
06/30/2026	08/06/2026	10-Q
03/31/2026	05/07/2026	10-Q
12/31/2025	03/03/2026	10-K
09/30/2025	11/14/2025	10-Q
06/30/2025	08/06/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	02/27/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/07/2024	10-Q
12/31/2023	03/19/2024	10-K
09/30/2023	11/07/2023	10-Q
06/30/2023	08/09/2023	10-Q
03/31/2023	05/09/2023	10-Q
12/31/2022	03/07/2023	10-K
09/30/2022	11/14/2022	10-Q

Collapse to Preview

Report Date	Filing Date	Filing
06/30/2026	08/06/2026	10-Q
03/31/2026	05/07/2026	10-Q
12/31/2025	03/03/2026	10-K
09/30/2025	11/14/2025	10-Q
06/30/2025	08/06/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	02/27/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/07/2024	10-Q
12/31/2023	03/19/2024	10-K
09/30/2023	11/07/2023	10-Q
06/30/2023	08/09/2023	10-Q
03/31/2023	05/09/2023	10-Q
12/31/2022	03/07/2023	10-K
09/30/2022	11/14/2022	10-Q
06/30/2022	08/08/2022	10-Q
03/31/2022	05/16/2022	10-Q
12/31/2021	03/07/2022	10-K
09/30/2021	11/09/2021	10-Q
06/30/2021	08/10/2021	10-Q
03/31/2021	05/13/2021	10-Q
12/31/2020	03/09/2021	10-K
09/30/2020	11/09/2020	10-Q
06/30/2020	08/07/2020	10-Q
03/31/2020	05/07/2020	10-Q
12/31/2019	03/12/2020	10-K
09/30/2019	11/12/2019	10-Q

Recent Forward Guidance

Updated 10/26/2026

Latest: Q2 2026 Earnings Reported 8/6/2026

null

Prior: Q1 2026 Earnings Reported 5/7/2026

Forward Guidance					Guidance Change
Metric	Source	Low	Mid	High	% Chg	% Delta	Change	Prior
Q3 2026 Commercial Supply Availability	Reported
2026 Phase 2 FORGE Trial Initiation	Reported
2026 SRK-439 Topline Data	Reported

Q4 2025 Earnings Reported 3/3/2026

Forward Guidance					Guidance Change
Metric	Source	Low	Mid	High	% Chg	% Delta	Change	Prior
Q1 2026 Debt Facility Drawdown	Reported		100.00 Mil
2026 Debt Facility Availability	Reported		150.00 Mil

Q4 2025 Earnings Reported 1/12/2026

Forward Guidance					Guidance Change
Metric	Source	Low	Mid	High	% Chg	% Delta	Change	Prior
2027 Cash Runway	Reported		2027

Insider Activity

Updated 9/25/2026

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Flier, Jeffrey S	Direct	Sell	7062026	53.88	3,053	164,490	1,500,832	Form
2	Burow, Kristina	Direct	Sell	7062026	53.74	3,053	164,064	6,161,502	Form
3	Reed, Joshua	Direct	Sell	7062026	53.74	3,053	164,067	1,048,892	Form
4	Peng, Katie	Direct	Sell	7062026	53.88	5,446	293,405	1,847,974	Form
5	Gilman, Michael	Direct	Sell	7062026	53.87	2,544	137,058	3,206,154	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Flier, Jeffrey S		Direct	Sell	7062026	53.88	3,053	164,490	1,500,832	Form
2	Burow, Kristina		Direct	Sell	7062026	53.74	3,053	164,064	6,161,502	Form
3	Reed, Joshua		Direct	Sell	7062026	53.74	3,053	164,067	1,048,892	Form
4	Peng, Katie		Direct	Sell	7062026	53.88	5,446	293,405	1,847,974	Form
5	Gilman, Michael		Direct	Sell	7062026	53.87	2,544	137,058	3,206,154	Form
6	Woods, Keith	Chief Operating Officer	Direct	Sell	4202026	49.57	10,220	506,651	30,738,917	Form
7	Vaishnaw, Akshay	President of R&D	Direct	Sell	4202026	49.57	12,246	607,089	31,258,804	Form
8	Sinha, Vikas	Chief Financial Officer	Direct	Sell	4202026	49.57	10,410	516,071	30,729,051	Form
9	Hallal, David	Chief Executive Officer	Direct	Sell	4202026	49.57	30,615	1,517,723	81,254,291	Form
10	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	2252026	47.07	8,484	399,351	4,633,909	Form
11	Parlavecchio, Caryn	CHRO	Direct	Sell	2192026	46.53	9,035	420,382	7,867,314	Form
12	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	2192026	46.53	7,989	371,714	4,975,214	Form
13	Marantz, Jing L	CHIEF MEDICAL OFFICER	Direct	Sell	2192026	46.53	4,157	193,418	5,863,112	Form
14	Ho, Junlin	GENERAL COUNSEL	Direct	Sell	2192026	46.53	9,580	445,740	11,238,654	Form
15	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	1232026	46.71	14,898	695,938	4,001,477	Form
16	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	1212026	44.48	8,406	373,880	4,472,589	Form
17	Parlavecchio, Caryn	CHRO	Direct	Sell	1212026	44.48	6,600	293,553	6,621,128	Form
18	Marantz, Jing L	CHIEF MEDICAL OFFICER	Direct	Sell	1212026	44.48	5,798	257,882	4,255,938	Form
19	Ho, Junlin	GENERAL COUNSEL	Direct	Sell	1212026	44.48	8,016	356,533	9,542,824	Form
20	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	1162026	45.20	13,112	592,611	4,924,748	Form
21	Sinha, Vikas	Chief Financial Officer	Direct	Sell	1152026	42.70	16,755	715,438	24,904,562	Form
22	Woods, Keith	Chief Operating Officer	Direct	Sell	1152026	42.70	16,746	715,054	24,904,946	Form
23	Vaishnaw, Akshay	President of R&D	Direct	Sell	1152026	42.70	20,438	872,703	25,439,251	Form
24	Hallal, David	Chief Executive Officer	Direct	Sell	1152026	42.70	57,450	2,453,115	65,828,242	Form
25	Peng, Katie		Direct	Sell	12182025	44.09	1,006	44,352	1,450,820	Form
26	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	12162025	39.92	29,599	1,181,634	21,159,862	Form
27	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	12052025	45.21	136,462	6,169,788	4,926,535	Form
28	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	10072025	38.65	113,025	4,368,808	19,343,703	Form
29	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	10072025	37.27	387,414	14,438,544	14,438,544	Form
30	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	9242025	30.67	3,353	102,846	3,342,242	Form
31	Peng, Katie		Direct	Sell	9172025	32.53	1,006	32,726	1,103,240	Form
32	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	9172025	33.52	3,178	106,527	3,764,866	Form

Investor Activity (13F)

Updated Oct 27, 2026

13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active Manager	Value	% of Portfolio	Total Positions	QoQ	Filing
Samsara Biocapital, LLC	$339.1 Mil	32.9%	22	Hold	13F
Redmile Group, LLC	$445.7 Mil	29.5%	35	ADD +73.7%	13F
Siren, L.L.C.	$532.2 Mil	14.8%	102	Hold	13F
Eagle Health Investments LP	$24.3 Mil	5.1%	26	ADD +36.0%	13F
First Turn Management, LLC	$21.9 Mil	2.5%	33	Hold	13F
Casdin Capital, LLC	$17.2 Mil	1.3%	40	ADD +34.6%	13F
Paradigm Biocapital Advisors LP	$60.3 Mil	1.2%	35	TRIM -60.0%	13F

Active Manager	Value	% of Portfolio	Total Positions	QoQ	Filing
Redmile Group, LLC	$445.7 Mil	29.5%	35	ADD +73.7%	13F
Eagle Health Investments LP	$24.3 Mil	5.1%	26	ADD +36.0%	13F
Casdin Capital, LLC	$17.2 Mil	1.3%	40	ADD +34.6%	13F

Active Manager	Value	% of Portfolio	Total Positions	QoQ	As Of	Filing
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	$33.9 Mil	3.0%	48	Exited	Dec 31, 2025	13F
Paradigm Biocapital Advisors LP	$60.3 Mil	1.2%	35	TRIM -60.0%	Mar 31, 2026	13F

Active Manager	Value	% of Portfolio	Total Positions	QoQ	Filing
Siren, L.L.C.	$532.2 Mil	14.8%	102	Hold	13F
Redmile Group, LLC	$445.7 Mil	29.5%	35	ADD +73.7%	13F
Samsara Biocapital, LLC	$339.1 Mil	32.9%	22	Hold	13F
Paradigm Biocapital Advisors LP	$60.3 Mil	1.2%	35	TRIM -60.0%	13F
Eagle Health Investments LP	$24.3 Mil	5.1%	26	ADD +36.0%	13F
First Turn Management, LLC	$21.9 Mil	2.5%	33	Hold	13F
Casdin Capital, LLC	$17.2 Mil	1.3%	40	ADD +34.6%	13F

SRRK Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Status	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

Diversification Alternatives

How Is The Market Pricing SRRK?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What SRRK Makes & Who Pays

TTM figures based on

SRRK Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 10/26/2026

Scholar Rock (SRRK)

Market Price (10/27/2026): $41.57 | Market Cap: $5.1 BilSector: Health Care | Industry: Biotechnology

Scholar Rock (SRRK)

Market Price (10/27/2026): $41.57Market Cap: $5.1 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

SRRK in ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Scholar Rock (SRRK)

Key Risks for Scholar Rock (SRRK)

Expected Drivers of Future Revenue Growth for Scholar Rock (SRRK)

Share Issuance

Inbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Scholar Rock (SRRK)

Peer Outperformance in Biotechnology

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Clinical Pipeline

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance

Insider Activity

Investor Activity (13F)

SRRK Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

Market Price (10/27/2026): $41.57
Market Cap: $5.1 Bil
Sector: Health Care
Industry: Biotechnology